Replies to post #244811 on Biotech Values

[DewDiligence]

MGTA—(-24%/AH)—pauses_phase-1/2_trial_in AML/MDS after_patient_death deemed “possibly drug-related”:

https://finance.yahoo.com/news/magenta-therapeutics-voluntarily-pauses-mgta-210500940.html

Magenta Therapeutics today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117.